ABSTRACT: BACKGROUND:Some weight loss medications, including liraglutide 3.0?mg, are thought to facilitate weight loss by improving appetite control. However, no studies have evaluated their long-term appetitive effects. SUBJECTS/METHODS:This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI?=?38.8?±?4.8?kg/m2) who participated in a 52-week trial. Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0?mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component). Participants rated their hunger, fullness after meals, liking of meals, and food preoccupation (all as experienced over the past week) using visual analogue scales (0-100?mm). Ratings were completed at baseline and eight subsequent visits over the year. RESULTS:At week 52, participants treated by IBT-alone lost 6.2?±?1.6% of baseline weight, compared with 11.8?±?1.6% and 12.1?±?1.5% in the IBT-liraglutide and Multi-component groups, respectively. Compared to IBT-alone, IBT-liraglutide participants reported larger reductions at week 6 in hunger (-0.3?±?4.2 vs -16.8?±?4.0?mm, p?=?.005) and food preoccupation (+0.2?±?3.7 vs -16.3?±?3.6?mm, p?=?.002) and larger increases in fullness (-5.1?±?3.2 vs +9.8?±?3.0?mm, p?=?.001). These significant differences persisted at all assessments through week 24. There were no differences between IBT-alone and IBT-liraglutide in meal liking. IBT-alone and Multi-component participants differed in hunger at week 6, and in food preoccupation at all assessments through week 24. Multi-component participants reported reduced liking of meals relative to the IBT-alone and IBT-liraglutide groups through weeks 40 and 52, respectively. There were no other differences among any groups at week 52. CONCLUSIONS:Consistent with short-term studies, IBT-liraglutide participants reported greater improvements in hunger, fullness, and food preoccupation than those assigned to IBT-alone. Differences in appetite persisted for 24 weeks but were not maintained at week 52, despite the relatively greater weight losses in the liraglutide-treated participants at the trial's end.
